Related Experiment Videos
E1a is an exogenous in vivo tumour suppressor
Francisco J Cimas1, Juan L Callejas-Valera2, Dolores C García-Olmo3
1Laboratorio de Oncología, Unidad de Medicina Molecular, PCYTCLM/Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Unidad Asociada de Biomedicina CSIC-UCLM, 02006 Albacete, Spain.
Cancer Letters
|April 19, 2017
Summary
Adenovirus E1a gene exhibits anti-tumor properties in vivo, contradicting its proposed oncogenic role. This finding supports its potential application in gene therapy for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- The adenovirus E1a gene is a significant tool in cancer research, with proposed roles as both an oncogene and a tumor suppressor.
- In vivo studies have shown E1a can delay tumor formation, suggesting a tumor suppressor function that contrasts with its in vitro oncogenic activity.
Purpose of the Study:
- To clarify the in vivo role of the adenovirus 5 E1a 13s isoform.
- To evaluate the anti-tumor effects of E1a in vivo using xenograft models and a transgenic mouse model.
Main Methods:
- Conventional xenograft approach using HCT116 and B16-F10 cells in immunosuppressed and immunocompetent mice.
- Engineering a transgenic mouse model with inducible E1a 13s expression controlled by cytokeratin 5.
Main Results:
- Consistent anti-tumor effects observed in xenograft models, irrespective of the mouse's immune status.
- E1a demonstrated an ability to block chemical skin carcinogenesis in the transgenic mouse model.
- The in vitro oncogenic role of E1a could not be extrapolated to its in vivo behavior.
Conclusions:
- The adenovirus E1a gene exhibits a significant in vivo anti-tumor effect.
- The study supports the potential of E1a as a therapeutic agent in gene therapy approaches for cancer.